Use of autologous platelet-rich plasma in knee osteoarthritis symptomatic treatment-Reference-Cited by-同舟云学术

Use of autologous platelet-rich plasma in knee osteoarthritis symptomatic treatment

Published:2023-12-02 Issue:4 Volume:20 Page:308-315
ISSN:2524-2350
Container-title:Proceedings of the National Academy of Sciences of Belarus, Medical series
language:
Short-container-title:Vescì Nac. akad. navuk Belarusì, Ser. med. navuk

Author:

Bukach D. V.¹^ORCID,Eismont O. L.¹^ORCID,Potapnev M. P.²^ORCID,Asaevich V. I.²^ORCID,Litskevich P. V.²^ORCID,Karpenko F. N.²^ORCID,Krivenko S. I.³^ORCID,Bogdan V. G.⁴^ORCID,Vusau V. V.⁵^ORCID,Hahelko K. E.⁶^ORCID

Affiliation:

1. Republican Scientific and Practical Center of Traumatology and Orthopedics

2. Republican Scientific and Practical Center of Transfusiology and Medical Biotechnologies

3. Minsk Scientific and Practical Center for Surgery, Transplantation and Hematology

4. National Academy of Sciences of Belarus

5. 6th City Clinical Hospital

6. Minsk Regional Clinical Hospital

Abstract

Among the conservative methods of treatment of osteoarthritis the use of plasma enriched with soluble platelet factors /platelet-rich plasma (PORFT/PRP) is becoming increasingly attractive.The aim of the study was to determine the tolerability and effect of intra-articular administration of standardized autologous PRP on patients with knee osteoarthritis status based on the survey results. Patients with knee osteoarthritis (OA) received standard drug therapy (n = 19) or additionally standardized autologous platelet-rich plasma (PRP) (n = 21). Intraarticular injection of 6 ml of PRP was carried out three times every two weeks. The administration safety was assessed. Patients were questioned with an assessment of VAS and WOMAC scales in 2 weeks, 1 month and 3 months after starting the treatment. It was shown that three-time intra-articular administration of standardized autologous PRP was safe for a patient. At the same time, the pain syndrome decreased (VAS score) and the knee joint function improved (WOMAC score) after 1 and 3 months. All indicators were significantly better compared to the control group. We concluded that standardized autologous PORFT with three intra-articular injections is safe and has an analgesic effect and preserves the function of the knee joint already within 1–3 months of observation.

Publisher

Publishing House Belorusskaya Nauka

Subject

General Medicine

Reference12 articles.

1. Karateev A. E., Lila A. M. Osteoarthritis: current clinical concept and some promising therapeutic approaches. Nauchno-prakticheskaya revmatologiya [Rheumatology science and practice], 2018, vol. 56, no. 1, pp. 70–81 (in Russian).

2. Filardo G., Previtali D., Napoli F., Candrian C., Zaffagnini S., Grassi A. PRP injections for the treatment of knee osteoarthritis: a meta-analysis of randomized controlled trials. Cartilage, 2021, vol. 13, suppl. 1, pp. 364S–375S. https://doi.org/10.1177/1947603520931170

3. Costa L. A. V., Lenza M., Irrgang J. J., Fu F. H., Ferretini M. How does platelet-rich plasma compare clinically to other therapies in the treatment of knee osteoarthritis? A systemic review and meta-analysis. American Journal of Sports Medicine, 2022, vol. 51, no. 4, pp. 1074–1086. https://doi.org/10.1177/03635465211062243

4. Kim J.-H., Park Y.-B., Ha C.-W. Are leukocyte-poor or multiple injections of platelet-rich plasma more effective than hyaluronic acid for knee osteoarthritis? A systemic review and meta-analysis of randomized controlled trials. Archives of Orthopaedic and Trauma Surgery, 2022, vol. 143, no. 7, pp. 3879–3897. https://doi.org/10.1007/s00402-022-04637-5

5. Potapnev M. P., Zagorodnyi G. M., Krivenko S. I., Bogdan V. G., Svirskii A. O., Yasyukevich A. S., Asaevich V. I., Bukach D. V., Eismont O. L. Modern aspects of the use of plasma enriched in soluble platelet factors in the treatment of injuries and diseases of the musculoskeletal system. Sportivnaya meditsina: nauka i praktika [Sports medicine: research and practice], 2019, vol. 9, no. 4, pp. 33–45 (in Russian).